261 related articles for article (PubMed ID: 11220986)
1. Oral antimicrobial susceptibilities of Streptococcus pyogenes recently isolated in five countries.
Bandak SI; Turnak MR; Allen BS; Bolzon LD; Preston DA
Int J Clin Pract; 2000 Nov; 54(9):585-8. PubMed ID: 11220986
[TBL] [Abstract][Full Text] [Related]
2. [Isolated susceptibility of Streptococcus pyogenes to 3 macrolides].
Sakran W; Raz R; Colodner R; Keness Y
Harefuah; 1997 Nov; 133(9):365-6, 414. PubMed ID: 9418339
[TBL] [Abstract][Full Text] [Related]
3. [Comparative in vitro activity of new oral macrolides against Streptococcus pyogenes strains].
Prado V; Romero J; Herrera N; Marinkovic K; Bustos R
Rev Med Chil; 1993 Oct; 121(10):1128-34. PubMed ID: 8191116
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility and macrolide resistance genes in Streptococcus pyogenes collected in Austria and Hungary.
Gattringer R; Sauermann R; Lagler H; Stich K; Buxbaum A; Graninger W; Georgopoulos A
Int J Antimicrob Agents; 2004 Sep; 24(3):290-3. PubMed ID: 15325435
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of Streptococcus pyogenes to two macrolides in northern Israel.
Sakran W; Raz R; Chazan B; Koren A; Colodner R
Int J Antimicrob Agents; 2004 May; 23(5):517-9. PubMed ID: 15120735
[TBL] [Abstract][Full Text] [Related]
6. [Macrolide antibiotic resistance rates and phenotypes of group A beta hemolytic streptococci isolated between the years 1999-2000 and 2001-2002].
Senses Z; Baysallar M; Gür D; Doğanci L
Mikrobiyol Bul; 2003 Oct; 37(4):225-34. PubMed ID: 14748258
[TBL] [Abstract][Full Text] [Related]
7. Activity of ceftibuten, cefaclor, azithromycin, clarithromycin, erythromycin and telithromycin against Streptococcus pyogenes clinical isolates with different genotypes and phenotypes.
Drago L; Ripa S; Zampaloni C; De Vecchi E; Vitali LA; Petrelli D; Prenna M
Chemotherapy; 2005 Aug; 51(5):268-71. PubMed ID: 16088124
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study.
Brown SD; Rybak MJ
J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i7-15. PubMed ID: 15265831
[TBL] [Abstract][Full Text] [Related]
9. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes. Artemis-Italy Study Group.
Varaldo PE; Debbia EA; Nicoletti G; Pavesio D; Ripa S; Schito GC; Tempera G
Clin Infect Dis; 1999 Oct; 29(4):869-73. PubMed ID: 10589905
[TBL] [Abstract][Full Text] [Related]
10. High macrolide resistance in Streptococcus pyogenes strains isolated from children with pharyngitis in China.
Liu X; Shen X; Chang H; Huang G; Fu Z; Zheng Y; Wang L; Li C; Liu L; Shen Y; Yang Y
Pediatr Pulmonol; 2009 May; 44(5):436-41. PubMed ID: 19360846
[TBL] [Abstract][Full Text] [Related]
11. [Susceptibility of Streptococcus pyogenes isolates from pharyngeal exudates in Cordoba (Spain)].
Gordillo RM; Lacasa MJ; Ibarra A; Rodríguez F; Casal M
Rev Esp Quimioter; 2003 Mar; 16(1):58-60. PubMed ID: 12750758
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
Amábile-Cuevas CF; Hermida-Escobedo C; Vivar R
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S30-2. PubMed ID: 11249826
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program.
Gracia M; Díaz C; Coronel P; Gimeno M; García-Rodas R; Rodríguez-Cerrato V; del Prado G; Huelves L; Ruiz V; Naves PF; Ponte MC; Granizo JJ; Soriano F
Diagn Microbiol Infect Dis; 2009 May; 64(1):52-6. PubMed ID: 19232860
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain.
Pérez-Trallero E; Fernández-Mazarrasa C; García-Rey C; Bouza E; Aguilar L; García-de-Lomas J; Baquero F;
Antimicrob Agents Chemother; 2001 Dec; 45(12):3334-40. PubMed ID: 11709305
[TBL] [Abstract][Full Text] [Related]
15. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001.
Bergman M; Huikko S; Pihlajamäki M; Laippala P; Palva E; Huovinen P; Seppälä H;
Clin Infect Dis; 2004 May; 38(9):1251-6. PubMed ID: 15127336
[TBL] [Abstract][Full Text] [Related]
16. [Streptococcus pyogenes: penicillin and erythromycin susceptibility in the cities of Neuquen and Cipolletti].
Soriano SV; Brasili S; Saiz M; Carranza C; Vidal P; Calderón J; Lopardo HA
Medicina (B Aires); 2000; 60(4):487-90. PubMed ID: 11188957
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.
Van Asselt GJ; Sloos JH; Mouton RP; Van Boven CP; Van de Klundert JA
J Med Microbiol; 1995 Nov; 43(5):386-91. PubMed ID: 7563004
[TBL] [Abstract][Full Text] [Related]
18. Erythromycin-resistant Streptococcus pyogenes in Argentina.
Lopardo HA; Hernandez C; Vidal P; Vazquez M; Rosaenz L; Rubinstein G; Smayevsky J; Tokumoto M; Fernandez Lausi A; Daher O; Kaufman S; Soriano SV; Brasili S; Bottiglieri M; Carranza MC
Medicina (B Aires); 2004; 64(2):143-5. PubMed ID: 15628302
[TBL] [Abstract][Full Text] [Related]
19. [Emergence of macrolide resistant Streptococcus pyogenes strains in pediatric patients in France].
Mariani-Kurkdjian P; Doit C; Deforche D; Brahimi N; Francois M; Van den Abbeele T; Bingen E
Pathol Biol (Paris); 2004 Oct; 52(8):489-92. PubMed ID: 15465270
[TBL] [Abstract][Full Text] [Related]
20. Macrolide prescriptions and erythromycin resistance of Streptococcus pyogenes.
Gagliotti C; Nobilio L; Milandri M; Moro ML;
Clin Infect Dis; 2006 Apr; 42(8):1153-6. PubMed ID: 16575736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
